 


Steve Aselage | Professional Profile
 


























 









LinkedIn



















































Main content starts below.




Steve AselageCEO RetrophinLocationGreater San Diego AreaIndustryBiotechnologyCurrentRetrophin, Acer Therapeutics Inc.PreviousBioMarin Pharmaceutical Inc, APT Pharmaceuticals, RenwoodEducationUniversity of Notre Dame500+ connectionsView Steve’s full profile. It's free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View Steve’s Full ProfileSteve’s ActivityJust the "push" many entrepreneurs need.  I know a lot of...Steve likedExperienceChief Executive OfficerRetrophinOctober 2014  –  Present (2 years 10 months)Chairman of the BoardAcer Therapeutics Inc.January 2016  –  Present (1 year 7 months)Board of DirectorsRetrophinOctober 2012  –  Present (4 years 10 months)EVP & CBOBioMarin Pharmaceutical Inc2005  –  October 2012 (7 years)Board of DirectorsAPT Pharmaceuticals2009  –  2011 (2 years)DirectorRenwood1994  –  2010 (16 years)Sr. VP Sales and MarketingCell Therapeutics, Inc2004  –  2005 (1 year)VP Sales and MarketingSangStat Medical1998  –  2003 (5 years)VP Sales and MarketingSangStat Medical Corporation/Genzyme1997  –  2002 (5 years)VP North America Sales and MarketingSangStat1997  –  2002 (5 years)Director of Sales and MarketingAdvanced Tissue Sciences1995  –  1997 (2 years)Director of SalesRPR Oncology1995  –  1996 (1 year)Director of SalesBoehringer Mannheim1993  –  1994 (1 year)Director SalesGenentech1986  –  1993 (7 years)SkillsOncologyFDAPharmaceutical IndustryBiotechnologyPharmaceutical SalesBusiness DevelopmentSales ManagementLifesciencesCross-functional Team LeadershipManaged CareMarketing StrategyGMPMedical DevicesStrategyProduct LaunchSee 16+CommercializationClinical TrialsStart-upsStrategic PlanningRegulatory AffairsProduct DevelopmentCardiologySalesHematologySales EffectivenessInfectious DiseasesDrug DevelopmentVaccinesTechnology TransferImmunologyValidationSee lessHow's this translation?Great•Has errorsThanks for your help!EducationUniversity of Notre DameBS, BiologyBS, Biology1969  –  1973GroupsOrphan Pharmaceuticals & Biopharmaceuticals GroupCONSTRUCTION CAREERS - MIDDLE EASTSoftware & Technology (#1 in Jobs, HR, Managers, Cloud, Mobile, Voice, CRM & Big Data)JOBSJAM - CONSTRUCTION RECRUITMENT EVENTSNotre Dame ScienceView Steve’s full profile to...See who you know in commonGet introducedContact Steve directlyView Steve’s Full ProfileNot the Steve you’re looking for? View moreView this profile in another languageEnglishGermanChinese (Simplified)People Also ViewedKeller PerryExecutive Assistant to Managing Director at General Catalyst PartnersEdwin Urrutiaretired. president and CEO of nothing.
Jennifer HuntVice President, Development Operations at RetrophinMartin ShkreliCEO at Godel Systems Inc, Founder at Turing Pharmaceuticals AGJane PitluckMartin ShkreliCEO on "Indefinite Leave of Absence"Deanna GreenActing General Counsel at Turing Pharmaceuticals AGMark CubanPresidentNancy RetzlaffSenior Commercial Leader - Pharmaceutical & Biotech IndustrySean ParkerPublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesFind a different Steve AselageFirst NameLast NameExample:  Steve AselageSteve AselageUnited StatesMore professionals named Steve AselageLinkedIn member directory:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country






















Stephen Aselage, Retrophin Inc: Profile & Biography - Bloomberg


































































  






























Feedback





Stephen "Steve" Aselage

President/CEO,
Retrophin Inc






Career History




President/CEO
Retrophin Inc, 11/2014-PRESENT


President/Interim CEO/COO
Retrophin Inc, 9/2014-10/2014


President/COO
Retrophin Inc, 5/2014-9/2014


Exec VP/Chief Business Officer
Biomarin Pharmaceutical Inc, 12/2009-9/2012


Senior VP:Global Comm Ops
Biomarin Pharmaceutical Inc, 6/2005-12/2009


Exec VP:Global Commercial Ops
Cell Therapeutics Inc, 2/2004-6/2005


Senior VP:North American Sales
Genzyme Corp, 9/2003-1/2004


Senior VP:North American Sales
Sangstat Medical Corp, 2/1999-9/2003


Director:Sales & Marketing
Advanced Tissue Sciences Inc, 1996-1/1999


Chief Executive Officer
Retrophin LLC, 10/2012-UNKNOWN



Rhone-Poulenc Rorer Pharmaceut, FORMER



Genentech Inc, FORMER



Bristol Laboratories Ltd, FORMER


Show More









Website:
www.retrophin.com






Corporate Information
Address:

777 Third Avenue
22nd Floor
New York, NY 10017
United States


Phone:
1-646-564-3680


Fax:
-


Web url:
www.retrophin.com











From The Web












Personal Information



Education



University of Notre Dame
Bachelor's Degree, Biology








Memberships



Board Memberships




Retrophin Inc


Board Member, 9/2012-PRESENT




Apt Pharmaceuticals Inc


Board Member, 1/2009-PRESENT









Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data










































Steve Aselage - Patara Pharma




























































































BOD

Steve Aselage




Mr. Aselage is the CEO of Retrophin, Inc. and a member of its board of directors. Prior to Retrophin, Mr. Aselage was EVP and CBO of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, he built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. He worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat. Earlier in his career, he held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) and Bristol Laboratories. Mr. Aselage received a BS in Biology from the University of Notre Dame.
















				MENU							



Home
Disease
Product
About
News
Contact







Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #115d1370-6ee8-11e7-854c-5734f83314d2
          





            Powered by
            PerimeterX
            , Inc.
          














Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #118c12b0-6ee8-11e7-82ed-9b6ea7a8e4dd
          





            Powered by
            PerimeterX
            , Inc.
          














Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #11bb8720-6ee8-11e7-b169-4710b87c016c
          





            Powered by
            PerimeterX
            , Inc.
          












	Retrophin Inc Names Stephen Aselage President And Chief Operations Officer













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Retrophin, Inc. (RTRX) Names Stephen Aselage President And Chief Operations Officer  











Tweet








5/28/2014 7:38:30 AM







Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Stephen Aselage as President and Chief Operations Officer, effective immediately. In his new role, Mr. Aselage will be responsible for managing corporate development activities, including the commercialization of existing products, building out the company’s global infrastructure, and exploring new business development opportunities. 

“Steve has been a trusted advisor to Retrophin since our formation, having served as a key member of our board of directors,” said Martin Shkreli, Founder and CEO of Retrophin. “I have no doubt that the expertise Steve has accumulated during his more than 30-year career in the global pharmaceutical industry will be invaluable as we continue advancing our pipeline of treatments for catastrophic diseases and expanding our commercial product portfolio through strategic transactions.”

“I’ve been impressed with Martin’s progress in building Retrophin over the past year and a half,” said Mr. Aselage. “As President and Chief Operations Officer, I look forward to sustaining this growth and helping the company realize the full potential of its promising treatments for rare and often life-threatening diseases.”

Prior to joining Retrophin in 2012, Mr. Aselage was Executive Vice President and Chief Business Officer at BioMarin Pharmaceutical, Inc. There, he built the commercial and medical affairs functions that launched three commercial products and developed commercial business in more than 45 countries.

Mr. Aselage has also held leadership roles with Sangstat Medical Corporation and Genentech. He worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat. Earlier in his career, he held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) and Bristol Laboratories. Mr. Aselage received his B.S. in biology from the University of Notre Dame.

About Retrophin

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's marketed products include Chenodal® and Vecamyl®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), schizophrenia, autism, infantile spasms, nephrotic syndrome and others. Retrophin intends to reintroduce Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection. For additional information, please visit www.retrophin.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect the Company's business. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.
Contacts

Retrophin, Inc.
Marc Panoff, 646-564-3671
CFO
marc@retrophin.com

Help employers find you! Check out all the jobs and post your resume.






                Read at
                BioSpace.com







Related News
Retrophin, LLC (RTRX) Initiates Global Access For RE-024 In Pantothenate Kinase-Associated Neurodegeneration (PKAN)  Organization Changes At Celgene (CELG) Have Got Investors Wondering Who Will Take Over Once Hugin Steps Down  Retrophin, LLC (RTRX) Completes Acquisition Of Manchester Pharmaceuticals, Inc. Update: Genelux Corporation Announces Former Amgen (AMGN) And Abbott Laboratories (ABT) Executives To Succeed Founder Aladar A. Szalay, Ph.D., As CEO, Chairman Of The Board  Retrophin, LLC (RTRX) Plunks Down $62.5 Million For Manchester Pharmaceuticals, Inc. Cleveland Biolabs Inc. (CBLI) Cuts Pay For Co-Founders And Directors To Conserve Cash  Retrophin, LLC (RTRX) Reports First Quarter 2014 Financial Results
  New Filings Reveal How Pfizer Inc. (PFE) Executives Made Millions Before Bid For AstraZeneca PLC (AZN)  Biotech Retrophin, LLC (RTRX) Files For $40 Million IPO  OXiGENE (OXGN) Names Experienced Biotech Executive, David J. Chaplin, Ph.D., As President And Chief Executive Officer  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Retrophin, Inc.




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 





























   Stephen Aselage | BioMarin Pharmaceutical Inc. | ZoomInfo.com

	Retrophin Announces Appointment Of Stephen Aselage As CEO













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Retrophin (RTRX) Announces Appointment Of Stephen Aselage As CEO  











Tweet








11/11/2014 8:50:35 AM


NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced that the Board of Directors has appointed Stephen Aselage as Chief Executive Officer (CEO), effective immediately. Mr. Aselage has been serving as the company’s interim CEO since September 30, 2014.

“Steve has done an excellent job of guiding Retrophin through a period of significant change,” said Steve Richardson, Chairman of the Board of Directors. “He has demonstrated compelling leadership and vision while working with the Board and management team to develop a plan that maximizes our commercial capabilities and focuses development efforts on assets with the highest potential returns. The Board is delighted that Steve has agreed to continue to lead Retrophin and execute our newly focused strategic plan.”

“I am honored to have the opportunity to continue working with the talented team at Retrophin as we bring life-changing treatments to our patients and value to our shareholders,” said Mr. Aselage. “I’ve gained a tremendous appreciation for our exceptional R&D capabilities, commercial talent, and highly effective business development efforts, all of which position Retrophin for continued success.”

Mr. Aselage has more than 30 years of pharmaceutical and biotechnology experience. Most recently, he was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, he built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences, and Genentech. He worked briefly for Genzyme as well, assisting in the transition following its acquisition of Sangstat. Earlier in his career, he held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) and Bristol Laboratories. Mr. Aselage received his B.S. in Biology from the University of Notre Dame.

About Retrophin

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Thiola® and Vecamyl®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), schizophrenia, infantile spasms, nephrotic syndrome and others. For additional information, please visit www.retrophin.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. No forward-looking statement can be guaranteed. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.

Contacts

Retrophin, Inc.
Marc Panoff, 646-564-3671
CFO
marc@retrophin.com
or
Chris Cline, CFA, 646-564-3680
Manager, Investor Relations
IR@retrophin.com

Help employers find you! Check out all the jobs and post your resume.






                Read at
                BioSpace.com







Related News
Retrophin (RTRX) Announces Divestment Of Non-Core Assets To Turing Pharmaceuticals Salix Pharmaceuticals, Ltd. (SLXP) Plummets As Accounting Scandal Sinks Deal With Allergan Inc. (AGN), CFO Resigns  Retrophin (RTRX) Booted CEO For Multiple Stock Violations: Report  Firing Of Sanofi (SAN.PA) CEO Mirrors Teva Pharmaceutical Industries Limited (TEVA)'s 2013 Shakeup  Retrophin, Inc. (RTRX), Gilead Sciences, Inc. (GILD), And Our Healthcare Values  Sanofi (SAN.PA) Ousts CEO After Clash Over Strategy  Retrophin, Inc. (RTRX) Announces Leadership Reorganization  Lpath, Inc. (LPTN) CEO Steps Down  Retrophin (RTRX) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  Sanofi (SAN.PA) Approached AstraZeneca PLC (AZN)'s Soriot For CEO Role  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Retrophin, Inc.




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 

































Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #1339c2b0-6ee8-11e7-b74b-412411c9cdb3
          





            Powered by
            PerimeterX
            , Inc.
          














Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #1373e580-6ee8-11e7-b29d-515e0feb0c6c
          





            Powered by
            PerimeterX
            , Inc.
          














Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #139db4a0-6ee8-11e7-bf7d-377c21a4f83b
          





            Powered by
            PerimeterX
            , Inc.
          










 


60+ Aselage profiles
 | LinkedIn
 




































LinkedIn



















































Main content starts below.




Aselage profilesShare on LinkedInShare on FacebookShare on TwitterShare on Google+Public ProfileSteve AselageCEO RetrophinLocationGreater San Diego AreaIndustryBiotechnologyCurrentChief Executive Officer at Retrophin, Chairman of the Board at Acer Therapeutics Inc., Board of Directors at RetrophinPastEVP & CBO at BioMarin Pharmaceutical Inc, Board of Directors at APT Pharmaceuticals, Director at Renwood, Sr. VP Sales and Marketing at...EducationUniversity of Notre DameView Full ProfilePublic ProfileElizabeth AselagePatient Advocacy & Alliance Development Specialist at RetrophinLocationGreater San Diego AreaIndustryBiotechnologyCurrentPatient Advocacy & Alliance Development Specialist at Retrophin, Discovery & Translational Research Analyst at Retrophin, Business...PastMuseum Officer at Michigan State University, Public Services Intern at Lansing Police Department, Court Officer at 30th Judicial Circuit...EducationMichigan State UniversitySummaryEmerging leader in the healthcare industry with expertise in strategic partnerships and program development from experiences working in the...View Full ProfilePublic ProfileHollie AselageBenefits Supervisor at BBRGLocationColumbus, Ohio AreaIndustryHuman ResourcesCurrentBenefits Supervisor at BRAVO BRIO Restaurant GroupPastHuman Resources Generalist at Charley's Grilled Subs, Human Resources/Payroll Manager at Rite Rug, Human Resources Coordinator at Bare...EducationThe Ohio State UniversitySummaryHighly motivated and compassionate Human Resources professional with several years of experience managing a full spectrum of human resource...View Full ProfilePublic ProfileSusan AselageBoard Member, Treasurer at St Louis MakesLocationGreater St. Louis AreaIndustryExecutive OfficeCurrentBoard Member, Treasurer at St. Louis Makes, Co Owner at Seabury FarmPastPresident and Vice Chairman of the Board at Sabreliner Corporation, Vice Chairman of the Board at Sabreliner Corporation, Vice President,...EducationWashington University in St. Louis - Olin Business School, Hobart and William Smith Colleges, Concord AcademySummarySusan joined Sabreliner Corporation at its inception in 1983 as its of the original investors.  
Her role as president included: developing...View Full ProfilePublic ProfileJenney AselageBusiness Analyst at Wells Fargo AdvisorsLocationGreater St. Louis AreaIndustryFinancial ServicesCurrentBusiness Analyst at Wells Fargo AdvisorsPastFinance Management Associate Program Intern at Bank of America, Intern at Armstrong Teasdale LLPEducationUniversity of Virginia, Mary Institute and St. Louis Country Day SchoolView Full ProfilePublic ProfileJustin AselageSenior Director, Business Intelligence - Finance at Corporate Executive BoardLocationWashington D.C. Metro AreaIndustryManagement ConsultingCurrentSenior Director, Business Intelligence - Finance at Corporate Executive BoardPastDirector / Assoc. Director, Business Intelligence at Corporate Executive Board, Senior Quantitative Analyst at Corporate Executive Board,...EducationUniversity of Delaware, University of ToledoSummarySpecialties: Well-versed in predictive analytic and data mining techniques, including multivariate regression, logistic regression, ANOVA,...View Full ProfilePublic ProfileMaria AselageCrisis Communications/PR ConsultantLocationCharleston, South Carolina AreaIndustryPublic Relations and CommunicationsCurrentOwner at HearSay Communications, Adjunct Professor/Director of Communications & Marketing - School of Business Administration at The...PastExecutive Vice President at Clay County Chamber of Commerce, Director of Communications & Information at Catholic Diocese of...EducationThe Citadel, The University of GeorgiaSummaryPublic relations professional with experience in coordinating crisis communications, overseeing communication initiatives for political...View Full ProfilePublic ProfileMatthew AselageLope Specialist and OAR Student Worker at Grand Canyon UniversityLocationOrange County, California AreaIndustryHigher EducationPastBackoffice Employee at Grand Canyon University, Lope Specialist at Grand Canyon University, Secretary, Treasurer, and Public Relations...EducationUniversity of California Irvine, Grand Canyon UniversityView Full ProfilePublic ProfileBrandon AselageSales Associate at MedtronicLocationGreater Detroit AreaIndustryMedical DevicesCurrentSales Associate at MedtronicPastBody Interior Engineer at Ford Motor Company, Biomechanics Research Intern at Foundation of Orthopaedic Research and Education (F.O.R.E) -...EducationUniversity of Michigan - Ann Arbor, University of Michigan College of EngineeringView Full ProfilePublic ProfileBill AselageOwner of Dream VacationsLocationJacksonville, Florida AreaIndustryLeisure, Travel & TourismCurrentFranchise Owner at Dream VacationsPastDistrict manager at Toshiba America Medical Systems, District Manager at Picker InternationalEducationXavier University - Williams College of Business, The Ohio State University Fisher College of BusinessSummaryI spent 35 years in the medical imaging field in sales and sales management. I retired and needed something to fill my spare time.

 I...View Full ProfilePublic ProfileJane AselageInterior Trim Manager - Body Engineering at Ford Motor CompanyLocationGreater Detroit AreaIndustryAutomotiveCurrentInterior Trim Manager - Body Engineering at Ford Motor CompanyView Full ProfilePublic ProfileBradley AselagePilot at Williams Aerial & MappingLocationLima, Ohio AreaIndustryInformation Technology and ServicesCurrentFlight Ops Director of Special Missions at Williams Aerial & MappingPastAerial Advertisement Pilot at Boomer AviationEducationSinclair Community CollegeSummaryDirector of Special mission

To make sure employees are able to operate high performance aircraft in photo mission based survey, over...View Full ProfilePublic ProfileScott Aselage, CPIMPlant Manager at HendricksonLocationFort Wayne, Indiana AreaIndustryTransportation/Trucking/RailroadCurrentPlant Manager at HendricksonPastMaterials Manager at Hendrickson Truck Suspension, Production Manager at Hendrickson Truck Suspension, Production Supervisor at Hendrickson...EducationIndiana University-Purdue University at Fort Wayne, Tri-State UniversityView Full ProfilePublic ProfileJohn Aselage A&A OrchardLocationFayetteville, Arkansas AreaIndustryFood ProductionCurrentSemi Retired at A&A OrchardPastManager Organic Agriculture at AMYS KITCHEN, INC., RAMP (Risk Avoidance and Mitigation) Panel Manager at USDA, Agricultural Research and...EducationMichigan State University, University of Missouri-Columbia, Antioch CollegeView Full ProfilePublic ProfileMason AselageSales Associate at OneSource SolutionsLocationGreater St. Louis AreaIndustryMarketing and AdvertisingCurrentCare Coordinator at Driftwood RecoveryPastSales Associate at OneSource SolutionsEducationTexas Tech University, Ladue Horton Watkins, Texas Tech University, Texas Tech UniversityView Full ProfilePublic ProfileTerry Aselage--LocationUnited StatesView Full ProfilePublic ProfileStephanie AselageEnvironmental Scientist at CH2M HillLocationCincinnati Area, KYIndustryEnvironmental ServicesCurrentEnvironmental Scientist at CH2M HillPastResearch Associate at University of Michigan, Environmental Scientist at LJB Inc.EducationUniversity of Michigan, Wright State UniversityView Full ProfilePublic ProfileGregory AselageApplication EngineerLocationCincinnati Area, KYIndustryComputer SoftwareCurrentApplication Engineer at Northrop Grumman CorporationEducationWright State UniversityView Full ProfilePublic ProfileJenifer AselageEnvironmental Engineer at Engineering & Environmental SolutionsLocationFort Wayne, Indiana AreaIndustryEnvironmental ServicesCurrentEnvironmental Engineer at Engineering & Environmental SolutionsPastEnvironmental Engineer at Avant Group, Environmental Engineer at Rivers Bend EngineeringEducationTri-State UniversityView Full ProfilePublic ProfileJoyce AselageQuality Laboratory Supervisor at The Dannon CompanyLocationLima, Ohio AreaIndustryConsumer GoodsCurrentQuality Laboratory Supervisor at The Dannon CompanyEducationWright State University, Urbana UniversityView Full ProfilePublic ProfileDarci AselageSelf EmployedLocationDayton, Ohio AreaIndustryManagement ConsultingPastClient Services Manager/Business Mentor at The Edge Retail Academy, Vice President at Harris JewelerEducationAnna High SchoolView Full ProfilePublic ProfileClem Aselage--LocationUnited StatesView Full ProfilePublic Profilekarl Aselagesales at weingartz supplyLocationGreater Detroit AreaIndustryMachineryCurrentsales at weingartz supplyPastowner at bighorn products westland mall, westland mich, sales at Allen Ford of West Bloomfield Mi, owner at Execu-Care Landscape Co,...Educationst. louis university, Loyola University New OrleansView Full ProfilePublic ProfileRick AselagePartner at RubinBrown LLPLocationGreater St. Louis AreaIndustryAccountingCurrentPartner at RubinBrown LLPEducationUniversity of Notre DameView Full ProfilePublic ProfileSteve AselageLocationSan Francisco Bay AreaIndustryBiotechnologyView Full ProfileJoin LinkedIn to see all 67 profiles.Join LinkedInJoin LinkedIn to see all 67 profiles.




















